301520.SZ
Anhui Wanbang Pharmaceutical Technology Co., Ltd.
SZSE · M 科研服务 · CN
CNY 51.86
+5.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 233.7M | 274.2M | 379.1M | 341.8M | 260.8M |
| Cost of Revenue | 180.5M | 203.2M | 229.1M | 174.5M | 129.4M |
| Gross Profit | 53.2M | 71.0M | 150.0M | 167.3M | 131.4M |
| Operating Expenses | |||||
| R&D Expense | 30.2M | 32.9M | 60.7M | 34.5M | 16.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 21.5M | 22.6M | 26.9M | 20.7M | 12.5M |
| Selling & Marketing Expense | 5.7M | 5.8M | 4.9M | 4.5M | 4.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 58.3M | 62.0M | 90.9M | 56.3M | 32.8M |
| Cost and Expenses | 238.8M | 265.1M | 319.9M | 230.8M | 162.2M |
| Operating Income (EBIT) | 27.9M | 41.5M | 87.0M | 119.0M | 106.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 22.3M | 35.9M | 89.5M | 119.6M | 111.1M |
| Income Tax Expense | (2.0M) | (581.3K) | 4.0M | 11.6M | 12.4M |
| Bottom Line | |||||
| Net Income | 24.3M | 36.4M | 85.5M | 108.1M | 98.7M |
| Earnings from Cont. Ops | 24.3M | 36.4M | 85.5M | 108.1M | 98.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 24.3M | 36.4M | 85.5M | 108.1M | 98.7M |
| Per Share | |||||
| Basic EPS | CN¥0.36 | CN¥0.55 | CN¥1.28 | CN¥2.00 | CN¥1.97 |
| Diluted EPS | CN¥0.36 | CN¥0.55 | CN¥1.28 | CN¥2.00 | CN¥1.97 |
| Revenue Per Share | CN¥3.48 | CN¥4.14 | CN¥5.67 | CN¥6.32 | CN¥5.20 |
| Shares | |||||
| Basic Shares Outstanding | 67.1M | 66.2M | 66.8M | 54.0M | 50.1M |
| Diluted Shares Outstanding | 67.1M | 66.2M | 66.8M | 54.0M | 50.1M |
| Profitability Metrics | |||||
| EBITDA | — | 61.3M | 106.0M | 131.4M | 113.3M |
| D&A | — | 19.8M | 19.0M | 12.3M | 7.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026